Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|November 5, 2015
Sanofi-Pasteur Awards Honor Research in Neglected Diseases and Immunology
November 05, 2015.
Advertisement
Sanofi and the Institut Pasteur have attributed this year's Sanofi-Institut Pasteur Awards to four major researchers for work in two major fields for global health: tropical and neglected diseases and immunology. The winners are
- Doctor Marco Vignuzzi, laureate in the Junior category, Viral Populations and Pathogenesis Research Unit, Institut Pasteur, Paris, France, and CNRS researcher, for his works on viral mutations presenting a short-term epidemic potential.
Link to the video
- Doctor Mohamed-Ali Hakimi, laureate in the Junior category, Host-Pathogen Interactions & Immunity to Infections, Institut Albert Bonniot, Université Grenoble Alpes, France, Inserm - CNRS, for his researches on the functioning of the parasite Toxoplama gondii responsible for toxoplasmosis.
Link to the video
- Professor Keith Matthews, laureate in the Mid-career category, Center for Immunity, Infection and Evolution, School of Biological Sciences, University of Edinburgh, United Kingdom, for his researches on the parasite Trypanosama brucei responsible for sleeping sickness.
Link to the video
- Professor Emil Unanue, laureate in the Senior category, Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, USA, for his work on the recognition of proteins by the immune system, paving the way to the research of therapies against autoimmune diseases such as type 1 diabetes, multiple sclerosis or rheumatoid polyarthritis.
Link to the video
Created in 2012, the Sanofi-Institut Pasteur Awards are the first international scientific prizes to honor researchers that are recognized both by an international academic research center and a leader in the pharmaceutical industry. The overall allocation of the prizes amount to €300,000 ($327,576).
The laureates received their Awards at a ceremony at the Institut Pasteur (Paris, France) last night.
Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement
Trending on PharmExec
1
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
4
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
5